An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Titre officiel

A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers

Sommaire:

The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab to participants with cancers that have failed to respond to or are known to be insensitive to T cell checkpoint inhibiting antibodies.

Description de l'essai

Primary Outcome:

  • Number of Participants With Dose-Limiting Toxicities (DLTs)
  • Number of Participants With Adverse Events (AEs), Serious AEs, AEs leading to Discontinuation and Deaths
  • Number of Participants With Clinically Significant Laboratory Abnormalities
Secondary Outcome:
  • Maximum Observed Plasma Concentration (Cmax) of BMS-986301
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) of BMS-986301
  • Area under the concentration-time curve in one dosing interval (24 h) of BMS-986301
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of BMS-986301
  • Changes in Levels and Activation of Tumour Infiltrating T Cells
  • Change in Programmed Death-Ligand 1 (PD-L1) Expression Status in Tumours
  • BMS-986301-induced Changes in Cytokines in Blood and Tumours

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer